KOSMAS started from a thorough understanding of leukemia pathogenesis and stem cell biology, which permitted the knowledge-driven design of a superior technology to benefit patients. Founder Georg Fey always intended to move his research to the clinic to create and develop new Trilytes for other cancers. Now, with a core team of experts, KOSMAS is doing just that.